ABSTRACT
Candida auris is an emerging multi-drug resistant yeast responsible for invasive infections among hospitalized patients. We described a case series of C. auris isolated in the Los Angeles area from an ongoing outbreak. Genomic analysis showed a single Clade III lineage of African origin in all 6 cases since 2019.
Introduction
Candida auris was first isolated in 2009 from the external ear canal of a 70-year-old patient in Tokyo, Japan1. In the decade that followed, cases of C. auris bloodstream and other invasive infections have been reported worldwide2,3,4,5,6,7. Many strains of C. auris are multidrug resistant and in some cases have elevated minimum inhibitory concentrations (MICs) to all three classes of antifungals including azoles, echinocandins and polyenes. The Centers for Disease Control and Prevention (CDC) recently listed C. auris as one of five “urgent threats” to public health in the 2019 Antibiotic Resistance (AR) Threats Report8, highlighting the need for active surveillance and appropriate infection prevention.
Whole genome sequencing (WGS) and phylogenetic analyses revealed the presence of at least four major clades of C. auris with worldwide geographic associations9,10. In the United States, outbreaks have been documented in New York, New Jersey, and Illinois; these were generally caused by strains of C. auris that were part of Clades I and IV11.
Here, we describe several cases of C. auris colonization and infection in patients of long-term acute care (LTAC) facilities in the Los Angeles area. WGS revealed that all isolates were part of Clade III, likely representing a unique outbreak in the United States. This is the first description of C. auris strains in Southern California.
Methods
A laboratory-developed polymerase chain reaction (PCR) test implemented by the clinical microbiology laboratory in September 2019, was used for the detection of C. auris from inguinal-axillary swabs and yeast isolates from positive fungal culture of clinical specimens as a means to actively screen high-risk patients transferred to UCLA from LTAC facilities and skilled nursing facilities (SNFs). Nucleic acid extraction using the EZ1 Tissue Extraction kit (Qiagen, Germantown, MD) was performed followed by PCR using the DiaSorin Molecular LIAISON® MDX platform (DiaSorin Molecular, Cypress, CA). PCR-positive swab specimens were cultured; yeast isolates were identified using VITEK MS MALDI-TOF system (bioMérieux Inc, Hazelwood, MO).
Antifungal susceptibility testing by broth microdilution was performed on panels prepared in-house according to Clinical and Laboratory Standards Institute (CLSI) standards. The CDC tentative MIC breakpoints were used for interpretation of the following drugs: amphotericin B (≥2µg/ml), fluconazole (≥32µg/ml), anidulafungin (≥4µg/ml), caspofungin (≥2µg/ml), micafungin (≥4µg/ml). Voriconazole, itraconazole, and posaconazole were also tested but no interpretative criteria for C. auris are available.
WGS was performed using Illumina MiSeq (Illumina, San Diego, CA). Analyses were performed using CLC Genomics Workbench (Qiagen, Valencia, CA, USA) and Geneious Prime (Biomatters, New Zealand). Reads were mapped to a reference C. auris complete genome (ATCC MYA-5002, NCBI: CP043531); this strain is part of Clade III. Sequences were compared by K-mer analysis and single nucleotide polymorphism (SNP) analysis using maximum-likelihood phylogenies.
This is a retrospective analysis and is part of an infection prevention and quality improvement project. The institutional review boards (IRB) approval was waived by the UCLA Office of the Human Research Protection Program.
Results
In one year (09/2019 – 09/2020), we screened 113 patients using our in-house C. auris PCR assay; six patients have tested positive for C. auris. Cycle threshold (Ct) values ranged from 22.6 to 39.7 (Table 1). Of the six PCR-positive patients, herein referred to as patients A through F, five tested positive between July and September 2020 (patients B-F); while patient A tested positive in October 2019.
All six patients were residents of 4 different LTAC facilities within the Los Angeles county area; all had history of tracheostomy. Patients A and F had prior history of C. auris colonization. The microbiological findings of each patient are described in Table 1. C. auris isolates grew from inguinal-axillary swabs of 4/6 patients (A, C, D, E) and from other clinical specimens of patients A (tracheal aspirate) and F (pleural fluid). We did not isolate C. auris from patient B (Ct=39.5).
All C. auris isolates were resistant to amphotericin B (MIC=2µg/ml) and fluconazole (MIC>64µg/ml) but susceptible to echinocandins (Table 2).
K-mer analysis was performed using 252 publicly available sequences of C. auris described previously12 (Supplemental Data 1) in addition to the sequences of the six isolates described here. All UCLA isolates belonged to Clade III (Supplemental Data 1). In this analysis, Clade III contained 56 isolates; these were primarily isolated from the African continent (n=44)11 (Supplemental Figure 1).
Isolates from all four clades have been identified in the US and show a geographic relationship11; Clade I is predominant. A k-mer phylogenetic analysis of 57 C. auris isolated in the US was performed (Figure 1). Clade III (n=7), which included the six UCLA isolates, had one additional isolate which originated from Indiana and was isolated in March of 2017 (Genbank accession # SRR7909359). SNP analysis showed that the UCLA isolates were closely related to one another (3-78 SNPs) as well as to the Indiana isolate (66 – 138 SNPs) (Supplemental Table 1).
To further characterize the C. auris isolates, we analyzed the sequence of two genes associated with antifungal resistance: erg11, which encodes lanosterol 14-alpha demethylase, and fks1, a subunit of 1,3-β-D-glucan synthase. Sequences of erg11 were identical for all UCLA isolates; all had a 99.6% pairwise nucleotide identity to the reference (CP043531) and two amino acid substitutions: V125A and F126L (Supplemental Table 2). Mutations at amino acid 126 are associated with increased azole resistance in C. auris 9 and are a common feature of Clade III isolates13. The specific F126L mutation appears to be exclusive to Clade III12. These findings are consistent with the antifungal susceptibility testing which showed that all isolates were resistant to fluconazole (Table 2). Sequences of fks1 were identical in five of the UCLA isolates (A1, A2, C1, D1, E1) and showed 99.9% pairwise nucleotide identity to the reference (CP043531); these isolates had one amino acid substitution: I1572L (Supplemental Table 2). Isolate UCLA_F1 had the same substitution in addition to I1095L. All isolates had a WT serine at amino acid 639; mutations at position 639 are linked to echinocandin resistance in C. auris14. All isolates were susceptible to caspofungin, micafungin and anidulafungin.
Discussion
Here, our use of an in-house PCR test to actively screen patients for C. auris colonization has proven to be vital in identifying and preventing the spread of this pathogen in our hospital system. WGS of isolates obtained from several patients of LTAC facilities revealed two important findings. First, these isolates are closely related to one another; this confirms the existence of an ongoing outbreak with community spread in the Los Angeles area. Second, these isolates are part of Clade III of African origin; this suggests a unique introduction of C. auris into the United States because this clade has not been implicated in outbreaks in other states.
The isolates described here were all resistant to fluconazole and Amphotericin B but susceptible to echinocandins. Additionally, all isolates had an F126L mutation in the erg11 gene, which is associated with fluconazole resistance and unique to Clade III strains of C. auris.
Limitations of this study include the lack of any additional epidemiological history of the patients related to exposures including travel. Being able to link patients to a country with known C. auris outbreaks of Clade III strains would be essential to understanding how the current Los Angeles outbreak began.
In conclusion, we have identified a unique Clade III C. auris strain in an ongoing outbreak in the LTAC facilities since 2019, indicating active community spread of multi-drug resistant C. auris in the Los Angeles area.
Data Availability
We are in the process of uploading the WGS data of the C. auris to NCBI.